ANTIPARASITIC DRUG DISCOVERY AND DEVELOPMENT

抗寄生虫药物的发现和开发

• 批准号: 6359025
• 负责人: JOAN E JACKSON
• 金额: $ 7.8万
• 依托单位: WALTER REED ARMY INSTITUTE OF RESEARCH
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-30 至 2001-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6359025
• 关键词: Africa; Leishmania; Trichomonas; Trypanosoma; antiprotozoal agents; bioassay; chemical structure function; cooperative study; drug discovery /isolation; drug screening /evaluation; medicinal plants; plant extracts; protein purification

Associate Program 4: Antileishmanial, Anti-trypanosomal, and Anti- trichomonad drug Discovery and Development take the ethnomedical, and later, ethnobotanical leads stepwise through in vitro bioassay guided purification of the active principles from medicinal herbs. Then follows with structure versus anti-parasite activity using either botanically related plants to those found active or pure compounds postulated to inhibit via a similar mechanism to that of the plant under study. Finally, this program guides the testing of the purified products, anti-parasite drug candidates through preliminary efficacy testing in rodents and higher animals and the collateral animal tests for undesirable toxicity. This program is structured to carry the ethnomedical "lead"compound through all stages of preclinical testing.

助理计划4：反智人，反try骨体和抗 Trichomonad药物发现和发展采用人类医学，以及 后来，民族植物学通过指导的体外生物测定逐步引导 从药草中纯化主动原理。然后跟随 使用两种植物学的结构与抗寄生虫活性 与发现的活性或纯化合物相关的植物 通过类似于所研究的植物的机制抑制。最后， 该程序指导纯化产品的测试，抗寄生虫 通过啮齿动物的初步疗效测试和较高的候选药物 动物和附带动物测试的不良毒性。这 程序的结构是通过所有人的种族中的“铅”化合物。 临床前测试的阶段。